NYSE - Delayed Quote USD

Labcorp Holdings Inc. (LH)

Compare
222.10 +1.86 (+0.84%)
At close: September 27 at 4:00 PM EDT
222.10 0.00 (0.00%)
After hours: September 27 at 6:21 PM EDT
Loading Chart for LH
DELL
  • Previous Close 220.24
  • Open 221.67
  • Bid 189.52 x 800
  • Ask 225.73 x 800
  • Day's Range 219.88 - 225.49
  • 52 Week Range 191.97 - 238.47
  • Volume 450,267
  • Avg. Volume 551,634
  • Market Cap (intraday) 18.648B
  • Beta (5Y Monthly) 1.04
  • PE Ratio (TTM) 41.36
  • EPS (TTM) 5.37
  • Earnings Date Oct 24, 2024
  • Forward Dividend & Yield 2.88 (1.30%)
  • Ex-Dividend Date Aug 29, 2024
  • 1y Target Est 256.29

Labcorp Holdings Inc. provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations (MCOs). In addition, the company offers online and mobile applications that enable patients to check test results; online applications for providers, MCOs, and accountable care organizations; specimen collection services; and drug development, medical device, and companion diagnostic development solutions, as well as support for crop protection and chemical testing. It serves pharmaceutical, biotechnology, medical device, and diagnostics companies; and MCOs, employer plans, other health insurance providers, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, crop protection and chemical companies, academic institutions, independent clinical laboratories, and retailers. The company was founded in 1995 is headquartered in Burlington, North Carolina.

www.labcorp.com

67,000

Full Time Employees

December 31

Fiscal Year Ends

Recent News: LH

View More

Performance Overview: LH

Trailing total returns as of 9/27/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

LH
1.29%
S&P 500
20.30%

1-Year Return

LH
9.62%
S&P 500
34.27%

3-Year Return

LH
9.96%
S&P 500
28.79%

5-Year Return

LH
59.80%
S&P 500
92.71%

Compare To: LH

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: LH

View More

Valuation Measures

Annual
As of 9/27/2024
  • Market Cap

    18.65B

  • Enterprise Value

    24.36B

  • Trailing P/E

    41.28

  • Forward P/E

    13.93

  • PEG Ratio (5yr expected)

    1.22

  • Price/Sales (ttm)

    1.52

  • Price/Book (mrq)

    2.33

  • Enterprise Value/Revenue

    1.95

  • Enterprise Value/EBITDA

    16.75

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    3.60%

  • Return on Assets (ttm)

    4.08%

  • Return on Equity (ttm)

    5.36%

  • Revenue (ttm)

    12.49B

  • Net Income Avi to Common (ttm)

    449.5M

  • Diluted EPS (ttm)

    5.37

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    265.1M

  • Total Debt/Equity (mrq)

    75.49%

  • Levered Free Cash Flow (ttm)

    801.65M

Research Analysis: LH

View More

Earnings Per Share

Consensus EPS
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

230.00
256.29 Average
222.10 Current
282.00 High
 

Company Insights: LH

Research Reports: LH

View More
  • Raising price target to $260

    LabCorp operates one of the largest global clinical laboratory networks, managing more than 160 million patient encounters each year, or more than 3 million patient specimens per week. LabCorp businesses also support clinical trial activity in approximately 100 countries. LabCorp has a market cap of about $18 billion. The company is a component of the S&P 500.

    Rating
    Price Target
     
  • U.S. stock indices are mostly in the red today, with investors perhaps

    U.S. stock indices are mostly in the red today, with investors perhaps experiencing a little 'green exhaustion' after the solid gains booked of late. Also of note, the meaningful news starts to hit the tape tomorrow with the release of the Fed minutes, so getting a little defensive in case the minutes include unwanted news is also defensible.

     
  • Daily – Vickers Top Buyers & Sellers for 08/08/2024

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

     
  • Labcorp Earnings: Solid Medical Utilization Contributes to Healthy Volume Gains

    Laboratory Corp. of America is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.

    Rating
    Price Target
     

People Also Watch